Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 9.4% in November

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 3,390,000 shares, a drop of 9.4% from the November 15th total of 3,740,000 shares. Based on an average daily trading volume, of 761,800 shares, the short-interest ratio is presently 4.4 days.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. TD Cowen lifted their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ ALNY traded up $0.18 during midday trading on Friday, reaching $245.44. 592,047 shares of the company’s stock were exchanged, compared to its average volume of 860,965. The stock has a market capitalization of $31.66 billion, a PE ratio of -93.68 and a beta of 0.32. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The business’s fifty day moving average price is $267.01 and its two-hundred day moving average price is $248.85.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.15 earnings per share. Analysts forecast that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock valued at $2,540,455 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Souders Financial Advisors grew its position in shares of Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 36 shares in the last quarter. Huntington National Bank boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the period. SYM FINANCIAL Corp increased its stake in Alnylam Pharmaceuticals by 6.2% during the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 55 shares during the last quarter. Lindbrook Capital LLC raised its holdings in shares of Alnylam Pharmaceuticals by 11.1% during the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 57 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 54.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 91 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.